Guanfacine Tablet, Extended Release
Product Images NDC 72266-256

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 72266-256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fosun Pharma Usa, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Stucture (Guanfacine 01)

Chemical structure of guanfacine hydrochloride, showing the molecular arrangement including two chlorine atoms, a ketone group, and a guanidine moiety associated with the HCl salt form.*

FDA Label Image

Figure 1 (Guanfacine 02)

A line graph depicting guanfacine plasma concentration (ng/mL) over 24 hours. It compares Guanfacine extended-release tablets 1 mg QD (solid line with squares) and Tenex 1 mg QD (dashed line with triangles). The x-axis represents time in hours, and the y-axis shows plasma concentration in ng/mL.*

FDA Label Image

Figure 2 (Guanfacine 03)

A pharmacokinetic fold change chart showing the impact of various CYP3A4/5 inhibitors, CYP3A4 inducers, and other substances on Cmax and AUC values relative to a reference. The chart includes data points with 90% confidence intervals for ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate.*

FDA Label Image

Figure 3 (Guanfacine 04)

A pharmacokinetic plot showing fold change and 90% confidence intervals for Cmax and AUC of two interacting drugs, Oral Methylphenidate and Lisdexamfetamine Dimesylate. The x-axis indicates change relative to reference from 0 to 2.0, with data points centered near 1.0, illustrating the impact on Guanfacine pharmacokinetics.*

FDA Label Image

Figure 3 (Guanfacine 05)

A line graph depicting treatment failure percentage over time in days, comparing placebo and SPD503 groups. The x-axis represents time to treatment failure (days), and the y-axis shows treatment failure percentage. The placebo is represented by a solid line, and SPD503 by a dashed line, illustrating differing treatment outcomes over approximately 200 days.*

FDA Label Image

1mg (Guanfacine 06)

Label for Guanfacine extended-release tablets USP, 1 mg strength, oral dosage form. The label states the product contains 100 tablets and includes storage instructions. It is distributed by Fosun Pharma USA Inc., Princeton, NJ, and manufactured in China. The label also advises that tablets should not be crushed, chewed, or broken before swallowing.*

FDA Label Image

2 mg (Guanfacine 07)

Label for Guanfacine Extended-Release Tablets, USP 2 mg oral tablets by Fosun Pharma USA, Inc. The label states 100 tablets per container and provides storage instructions and prescribing information references. The product is made in China and distributed by Fosun Pharma USA, Inc.*

FDA Label Image

3 mg (Guanfacine 08)

Label for Guanfacine Extended-Release Tablets, USP 3 mg by Fosun Pharma USA, Inc. The label indicates 100 tablets per container with instructions not to crush, chew, or break tablets before swallowing. It includes storage information, manufacturer details, and a note that the product contains FD&C Yellow No. 5 as a color additive.*

FDA Label Image

4 mg (Guanfacine 09)

Label for Guanfacine Extended-Release Tablets, USP 4 mg oral tablets, containing 100 tablets per container. The label indicates they should not be crushed, chewed, or broken, and include FD&C Yellow No. 5 (tartrazine) as a color additive. Distributed by Fosun Pharma USA Inc., Princeton, NJ, and made in China. Packaging includes storage instructions and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.